DBV Technologies S.A (DBVT) Stock
DBV Technologies S.A Chart
Company Profile
Price: $5.21
Market Cap: $106.89M
Exchange: NASDAQ
CEO: Mr. Daniel Tassé
Sector: Healthcare
Industry: Biotechnology
Employees: 108
Headquarters: Montrouge, None
Website: DBV Technologies S.A
Business Summary
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
DBV Technologies S.A News
DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress
Châtillon, France, February 25, 2025 DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the company will participate in the American Academy of Allergy, Asthma, and Immunology and World Allergy Organization (AAAAI/WAO) Joint Congress, February 28-March 3, 2025, in San Diego, CA. An oral abstract presentation by Dr. David Fleischer, FAAAAI, FACAAI, Professor of Pediatrics at Children's Hospital Colorado, will describe Month 60 (M60), end-of-study efficacy and safety results from PEOPLE (the open-label extension of the 12-month, double-blind placebo-controlled, Phase 3 PEPITES study in peanut allergic children aged 4-11 years).
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
AMF Regulated Information Châtillon, France, January 13, 2025 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF. Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appeared on the liquidity account as of December 31, 2024: 266,868 DBV Technologies shares, € 106,930.51.
DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old
Châtillon, France, December 11th, 2024 DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old DBV and FDA aligned on key study design elements for the COMFORT Toddlers study in 1 – 3 year-olds, including study size and wear time collection methodology and analysis COMFORT Toddlers study on-track to initiate in 2Q 2025 Viaskin Peanut patch BLA submission for the Toddlers indication anticipated for 2H 2026 FDA confirmed criteria for post-marketing confirmatory study in toddlers 1 – 3 years-old Company to host investor webcast today at 5:00pm ET DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the successful outcome of recent written and oral communication with the U.S. Food and Drug Administration (FDA) that provides a clear and well-defined regulatory pathway for the Viaskin Peanut patch program in toddlers 1 – 3-years-old. The FDA has formalized guidance on an Accelerated Approval for the Viaskin Peanut patch in toddlers 1 – 3-years-old.
DBV Technologies Announces Plan to Implement ADS Ratio Change
Châtillon, France, November 11, 2024 DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J200), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares (the “ADS Ratio”), nominal value €0.10 (ten cents) per share, from the current ADS Ratio of one (1) ADS to one (1) ordinary share to a new ADS Ratio of one (1) ADS to five (5) ordinary shares (the “ADS Ratio Change”). The Company anticipates that the ADS Ratio Change will be effective on or about November 29, 2024 (the “Effective Date”).
DBV Technologies Reports Third Quarter 2024 Financial Results
Châtillon, France, November 6, 2024 DBV Technologies Reports Third Quarter 2024 Financial Results DBV closes Q3 2024 with a cash balance of $46.4 million; cash runway into Q1 2025 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J200), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter of 2024. The quarterly and nine months financial statements were approved by the Board of Directors on November 6, 2024.
DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe
Châtillon, France, October 22, 2024 DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe DBV to pursue an Accelerated Approval pathway for toddlers ages 1 – 3 years-old BLA submission under Accelerated Approval is subject to completion of a six-month supplemental safety study in toddlers to be initiated in Q2 2025 VITESSE Phase 3 study evaluating the Viaskin Peanut patch in children ages 4 – 7 years-old exceeded enrollment goals; Topline results on track for 4Q 2025 European Medicines Agency (EMA) scientific advice confirms registration path for a Marketing Authorization Application (MAA) with the modified Viaskin peanut patch for a 1 – 7 year-old indication in Europe Company to host investor conference call at 5:00pm ET today DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced positive regulatory updates for the Viaskin Peanut patch in the United States and Europe. DBV has agreed to guidance provided by the U.S. Food and Drug Administration (FDA) on a pathway under the Accelerated Approval Program for the Viaskin Peanut patch in toddlers ages 1 – 3 years-old and has also received scientific advice from the EMA on a 1 – 7 year-old indication in Europe.
DBV Technologies to Participate in Upcoming ACAAI 2024 Congress
Châtillon, France, October 18, 2024 DBV Technologies to Participate in Upcoming ACAAI 2024 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, October 24 – 28th, 2024 in Boston, Massachusetts. This year's meeting will feature a “Product Theater” on What Defines an Optimal Peanut Allergy Treatment?
DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial
Châtillon, France, September 23, 2024 DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial In Q3 2024, DBV exceeded its recruitment goal and successfully closed the screening process for the VITESSE Phase 3 study evaluating the Viaskin ® Peanut Patch in peanut allergic children ages 4 – 7 years old Topline results of VITESSE data are expected by Q4 2025 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that patient screening is complete for the Phase 3 trial, VITESSE ( V iaskin Peanut I mmunotherapy T rial to E valuate S afety, S implicity and E fficacy), using the modified Viaskin Peanut Patch in children ages 4 – 7 years old with peanut allergy. “We are thrilled to have reached this significant milestone,” said Dr. Pharis Mohideen, Chief Medical Officer of DBV Technologies.
DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Châtillon, France, September 4, 2024 DBV Technologies to Participate in the H.C. Wainwright 26 th Annual Global Investment Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the H.C.
DBV Technologies S.A. (DBVT) Q2 2024 Earnings Call Transcript
DBV Technologies S.A. (NASDAQ:DBVT ) Q2 2024 Earnings Conference Call July 30, 2024 5:30 PM ET Company Participants Katie Matthews – Investor Relations Daniel Tassé – Chief Executive Officer Pharis Mohideen – Chief Medical Officer Virginie Boucinha – Chief Financial Officer Conference Call Participants Jon Wolleben – Citizens JMP Operator Welcome to the DBV Second Quarter Financial Results and Business Update Conference Call.
DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report
Châtillon, France, July 30, 2024 DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced the filing, for the semester ended June 30, 2024, of its Half-Year Report with the French market authority, “Autorité des Marchés Financiers” (“AMF”). The 2024 Half-Year Report can be consulted or downloaded from the Company's website (www.dbv-technologies.com) in the section Investors/Financial Information, and on the AMF website (www.amf-france.org), in French only.
DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results
Châtillon, France, July 30, 2024 DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results VITESSE enrollment in peanut allergic 4-7-year-olds is on-track and recruitment is expected to be complete by end of Q3 2024 DBV submitted a labeling proposal, informed by the EPITOPE efficacy data, to the Food and Drug Administration (FDA) to address the FDA's protocol queries regarding patch wear-time in COMFORT Toddlers DBV closes Q2 2024 with a cash balance of $66.2 million; due to cost-saving measures, the Company's cash runway is extended into Q1 2025 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today shared an update on the Phase 3 study, VITESSE ( V iaskin Peanut I mmunotherapy T rial to E valuate S afety, S implicity and E fficacy), using the modified Viaskin Peanut Patch, in children ages 4 – 7 years old with peanut allergy. The Company also provided a status update on the COMFORT (Characterization of the Optimal Management of FOod allergy Relief and Treatment) Toddlers supplemental safety study in 1 – 3-year-olds with peanut allergy.
DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024
Châtillon, France, July 29, 2024 DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, July 30th, at 5:30 p.m. ET to review its second quarter 2024 financial results and provide a business update.
DBV Technologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Châtillon, France, June 5, 2024 DBV Technologies to Participate in the Goldman Sachs 45 th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the 45th Annual Goldman Sachs Global Healthcare Conference on Monday, June 10th, at 8:00 am EDT, as well as in one-on-one investor meetings. A live webcast of the presentation can be accessed here, and will also be available on the Events section of Company's Investors website: https://dbv-technologies.com/investor-overview/events/ A replay will also be available on DBV Technologies' website for 90 days after the event.
DBV Technologies to Participate in Upcoming EAACI 2024 Congress
Châtillon, France, May 30, 2024 DBV Technologies to Participate in Upcoming EAACI 2024 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced its upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress May 31 – June 3 in Valencia, Spain. A flash talk presentation by Nicolette Arends, M.D.
DBV Technologies Announces Results of its 2024 Combined General Meeting
Châtillon, France, May 16, 2024 DBV Technologies Announces Results of its 2024 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, held its Combined General Meeting (the “General Meeting”). The General Meeting was chaired by Michel de Rosen, Chairman of the Company.
DBV Technologies to Participate in Upcoming Investor Conferences
Montrouge, France, May 9, 2024 DBV Technologies to Participate in Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced Daniel Tassé, Chief Executive Officer, will deliver a company presentation at two investor conferences in May. Citizens JMP Life Sciences Conference – May 13, 2024 Format: Fireside Chat Time: 11:00am ETLocation: Hilton Midtown Hotel, New York, NY H.C.
DBV Technologies Reports First Quarter 2024 Financial Results and Business Update
Montrouge, France, May 7, 2024 DBV Technologies Reports First Quarter 2024 Financial Results and Business Update VITESSE enrollment on track to screen last patient by Q3 2024 Appointment of Robert Pietrusko, PharmD to Chief Regulatory Officer Q1 2024 closes with a cash balance of $101.5 million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the first quarter 2024. The quarterly financial statements were approved by the Board of Directors on May 7, 2024.
Combined General Meeting of May 16, 2024
Châtillon, France, April 25, 2024 Combined General Meeting of May 16, 2024 Procedures for Obtaining Information and Preparatory Documents for the Combined General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), will hold its Combined General Meeting (the “General Meeting”) on May 16, 2024, at 10:00 a.m. CET at the Company's new headquarters located at IRO Building, 107 Avenue de la République, 92320 Châtillon, France.
DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document
Montrouge, France, March 8, 2024 DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced the filing, for the year ended December 31, 2023, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“URD”) with the French market authority, “Autorité des Marchés Financiers” (“AMF”). These documents can be accessed on the Investors section of the Company's website at www.dbv-technologies.com.
DBV Technologies Reports Full Year 2023 Financial Results and Business Update
Montrouge, France, March 7, 2024 DBV Technologies Reports Full Year 2023 Financial Results and Business Update Advanced Viaskin™ Peanut clinical development programs in peanut-allergic toddlers (1 through 3 years old) and children (4 through 7 years old) Strengthened executive leadership team in preparation for BLA submission Reported cash and cash equivalents of $141 million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the full year 2023. The audit procedures have been substantially completed by the Company's statutory auditors and financials – prepared under both US GAAP and IFRS for the purpose of Form 10-K and Universal Registration Document respectively – were approved by the Board of Directors on March 7, 2024.
DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024
Montrouge, France, March 4, 2024 DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatments for food allergies, today announced the Company will host a conference call and live audio webcast on Thursday, March 7th, at 5:00 p.m. ET to review full year 2023 financial results and provide a business update.
DBV Technologies to Participate in Upcoming AAAAI 2024 Congress
Montrouge, France, February 20 2024 DBV Technologies to Participate in Upcoming AAAAI 2024 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 –NASDAQ: DBVT), a clinical-stage biopharmaceutical company focused on treatments for food allergies, today announced two presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting, February 23-26 in Washington, D.C. A poster presentation by David Fleischer, M.D.
DBV Technologies S.A Earnings
This section highlights DBV Technologies S.A's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q2 | 2024 | 2024-07-30 | $-1.30 | $-1.70 |
| Read Transcript | Q4 | 2023 | 2024-03-07 | $-0.32 | $-0.12 |
| Read Transcript | Q3 | 2023 | 2023-10-31 | $-0.30 | $-0.18 |
| Read Transcript | Q2 | 2023 | 2023-07-31 | $-0.26 | $-0.26 |
Financial Statements
Access annual & quarterly financial statements for DBV Technologies S.A, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Revenue | $15.73M | $4.80M | $5.71M | $- | $- |
| Cost of Revenue | $- | $20.30M | $9.27M | $18.82M | $3.09M |
| Gross Profit | $15.73M | $-15.50M | $-3.57M | $-18.82M | $-3.09M |
| Gross Profit Ratio | 100.00% | -322.90% | -62.50% | 0.00% | 0.00% |
| Research and Development Expenses | $60.22M | $75.50M | $70.34M | $124.61M | $129.00M |
| General and Administrative Expenses | $25.16M | $24.30M | $30.52M | $41.87M | $55.77M |
| Selling and Marketing Expenses | $-2.28M | $1.60M | $4.39M | $12.12M | $24.07M |
| Selling General and Administrative Expenses | $22.88M | $25.90M | $34.91M | $53.98M | $79.85M |
| Other Expenses | $- | $- | $- | $-12.67M | $-16.04M |
| Operating Expenses | $92.16M | $101.40M | $105.24M | $165.92M | $192.80M |
| Cost and Expenses | $92.16M | $101.40M | $105.24M | $165.92M | $192.80M |
| Interest Income | $3.78M | $406.29K | $440.79K | $- | $85.15K |
| Interest Expense | $- | $427.00K | $583.76K | $887.89K | $1.79M |
| Depreciation and Amortization | $-4.57M | $20.30M | $9.27M | $18.82M | $3.09M |
| EBITDA | $-87.46M | $-76.68M | $-79.77M | $-162.74M | $-181.37M |
| EBITDA Ratio | -556.11% | -2012.50% | -1759.90% | 0.00% | 0.00% |
| Operating Income | $-76.43M | $-96.63M | $-98.61M | $-194.80M | $-192.80M |
| Operating Income Ratio | -485.97% | -2013.15% | -1727.65% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $3.71M | $431.00K | $8.99M | $-24.67M | $9.20M |
| Income Before Tax | $-72.72M | $-96.20M | $-98.19M | $-195.69M | $-194.51M |
| Income Before Tax Ratio | -462.35% | -2004.17% | -1720.22% | 0.00% | 0.00% |
| Income Tax Expense | $7.00K | $100.00K | $-381.00K | $-12.26K | $692.67K |
| Net Income | $-72.73M | $-96.30M | $-97.81M | $-195.68M | $-195.20M |
| Net Income Ratio | -462.40% | -2006.25% | -1713.54% | 0.00% | 0.00% |
| EPS | $-0.71 | $-1.24 | $-1.78 | $-3.62 | $-5.28 |
| EPS Diluted | $-0.71 | $-1.24 | $-1.78 | $-3.62 | $-5.28 |
| Weighted Average Shares Outstanding | 95.12M | 77.38M | 55.10M | 54.09M | 37.01M |
| Weighted Average Shares Outstanding Diluted | 95.12M | 77.38M | 55.10M | 54.09M | 37.01M |
| SEC Filing | Source | Source | Source | Source | Source |
Income Statement Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $1.16M | $1.41M | $8.88M | $2.40M | $2.29M | $2.19M | $-1.30M | $2.07M | $1.53M | $2.55M | $5.71M | $1.32M | $-1.49M | $2.94M | $-1.21M | $4.16M | $3.61M | $4.72M | $1.90M |
| Cost of Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit | $- | $1.16M | $1.41M | $8.88M | $2.40M | $2.29M | $2.19M | $-1.30M | $2.07M | $1.53M | $2.55M | $5.71M | $1.32M | $-1.49M | $2.94M | $-1.21M | $4.16M | $3.61M | $4.72M | $1.90M |
| Gross Profit Ratio | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research and Development Expenses | $23.66M | $25.37M | $21.40M | $12.78M | $13.80M | $17.62M | $16.04M | $29.61M | $15.10M | $18.61M | $12.22M | $11.67M | $16.32M | $20.18M | $22.16M | $26.39M | $25.75M | $21.93M | $27.53M | $37.54M |
| General and Administrative Expenses | $6.05M | $7.20M | $6.43M | $6.44M | $6.20M | $6.95M | $5.24M | $4.77M | $3.05M | $5.28M | $3.70M | $14.75M | $4.80M | $4.92M | $9.68M | $16.99M | $3.23M | $5.58M | $11.11M | $12.97M |
| Selling and Marketing Expenses | $- | $- | $758.00K | $825.00K | $700.00K | $516.00K | $434.00K | $51.00K | $159.00K | $1.04M | $464.00K | $1.39M | $1.07M | $1.20M | $729.00K | $1.76M | $1.59M | $-778.00K | $7.30M | $8.84M |
| Selling General and Administrative Expenses | $6.05M | $7.20M | $6.43M | $6.44M | $6.90M | $6.95M | $5.24M | $4.77M | $3.05M | $5.28M | $4.17M | $16.14M | $5.87M | $6.12M | $10.41M | $18.76M | $4.83M | $4.80M | $18.41M | $21.81M |
| Other Expenses | $614.00K | $2.43M | $- | $- | $- | $- | $-112.00K | $3.63M | $-126.00K | $-68.00K | $381.00K | $-192.00K | $3.50M | $5.21M | $-2.94M | $- | $- | $- | $- | $-3.21M |
| Operating Expenses | $30.33M | $35.00M | $28.56M | $12.02M | $20.70M | $25.08M | $21.16M | $38.02M | $18.02M | $23.82M | $16.77M | $20.11M | $24.37M | $31.13M | $29.64M | $37.61M | $30.05M | $26.41M | $41.22M | $55.22M |
| Cost and Expenses | $30.33M | $35.00M | $28.56M | $12.02M | $20.70M | $25.08M | $21.16M | $38.02M | $18.02M | $23.82M | $16.77M | $20.11M | $24.37M | $31.13M | $29.64M | $37.61M | $30.05M | $26.41M | $41.22M | $55.22M |
| Interest Income | $- | $726.00K | $1.26M | $730.00K | $1.50M | $846.00K | $605.00K | $427.00K | $732.00K | $784.00K | $152.00K | $- | $- | $46.00K | $215.00K | $724.00K | $- | $- | $309.00K | $-533.05K |
| Interest Expense | $- | $- | $- | $- | $- | $- | $- | $- | $732.00K | $784.00K | $152.00K | $- | $- | $- | $- | $68.00K | $- | $506.00K | $- | $731.88K |
| Depreciation and Amortization | $-152.00K | $-1.46M | $53.00K | $-10.93M | $-3.44M | $597.00K | $-228.00K | $12.02M | $-109.00K | $1.85M | $-599.00K | $-1.33M | $1.09M | $7.14M | $1.48M | $-7.90M | $3.77M | $13.05M | $1.55M | $2.24M |
| EBITDA | $-28.64M | $-33.79M | $-28.50M | $-10.34M | $-18.30M | $-24.48M | $-19.08M | $-25.99M | $-17.64M | $-21.98M | $-13.85M | $-15.32M | $-23.28M | $-24.00M | $-28.15M | $-69.06M | $-26.28M | $-13.36M | $-39.67M | $-53.51M |
| EBITDA Ratio | 0.00% | -2910.34% | -1878.04% | -116.54% | -762.50% | -973.78% | -869.78% | 1993.40% | -774.78% | -1437.34% | -543.79% | -268.36% | -1577.25% | 1612.77% | -957.26% | 5488.12% | -639.01% | 219.64% | -840.55% | -2819.68% |
| Operating Income | $-30.33M | $-33.84M | $-28.56M | $-11.92M | $-18.30M | $-25.08M | $-21.16M | $-38.02M | $-18.02M | $-23.82M | $-16.77M | $-13.48M | $-24.37M | $-31.13M | $-29.63M | $-40.16M | $-29.77M | $-47.69M | $-41.22M | $-55.22M |
| Operating Income Ratio | 0.00% | -2914.90% | -2029.71% | -134.31% | -762.50% | -1095.98% | -964.68% | 2915.41% | -868.85% | -1558.08% | -658.72% | -236.11% | -1841.87% | 2092.34% | -1007.62% | 3313.61% | -715.85% | -1321.16% | -873.35% | -2909.79% |
| Total Other Income Expenses Net | $-114.00K | $726.00K | $1.26M | $728.00K | $1.47M | $846.00K | $604.00K | $-1.24M | $733.00K | $784.00K | $152.00K | $-173.00K | $335.00K | $46.00K | $216.00K | $-1.89M | $-897.00K | $-21.79M | $309.00K | $-4.44M |
| Income Before Tax | $-30.44M | $-33.12M | $-27.30M | $-11.19M | $-16.80M | $-24.23M | $-20.56M | $-39.26M | $-17.29M | $-23.04M | $-16.62M | $-13.65M | $-24.03M | $-31.09M | $-29.42M | $-39.51M | $-30.95M | $-48.20M | $-40.91M | $-56.48M |
| Income Before Tax Ratio | 0.00% | -2852.37% | -1940.09% | -126.11% | -700.00% | -1059.00% | -937.15% | 3010.58% | -833.51% | -1506.80% | -652.75% | -239.14% | -1816.55% | 2089.25% | -1000.31% | 3259.74% | -744.30% | -1335.18% | -866.80% | -2976.45% |
| Income Tax Expense | $- | $- | $48.00K | $-6.00K | $-100.00K | $13.00K | $1.71M | $-17.00K | $-733.00K | $-784.00K | $87.00K | $23.00K | $2.42M | $-434.00K | $30.00K | $-20.00K | $7.00K | $3.00K | $- | $600.81K |
| Net Income | $-30.44M | $-33.12M | $-27.34M | $-11.19M | $-16.70M | $-24.24M | $-22.27M | $-39.24M | $-16.55M | $-22.25M | $-16.71M | $-13.67M | $-24.03M | $-30.65M | $-29.45M | $-39.48M | $-30.95M | $-48.20M | $-40.91M | $-57.08M |
| Net Income Ratio | 0.00% | -2852.37% | -1943.50% | -126.04% | -695.83% | -1059.57% | -1014.90% | 3009.28% | -798.17% | -1455.53% | -656.17% | -239.54% | -1816.55% | 2060.08% | -1001.33% | 3257.76% | -744.47% | -1335.26% | -866.80% | -3008.11% |
| EPS | $-0.32 | $-0.34 | $-0.28 | $-0.12 | $-0.17 | $-0.26 | $-0.24 | $-0.42 | $-0.18 | $-0.34 | $-0.30 | $-0.25 | $-0.44 | $-0.56 | $-0.54 | $-0.72 | $-0.56 | $-0.88 | $-0.79 | $-1.04 |
| EPS Diluted | $-0.32 | $-0.34 | $-0.28 | $-0.12 | $-0.17 | $-0.26 | $-0.24 | $-0.42 | $-0.18 | $-0.34 | $-0.30 | $-0.25 | $-0.44 | $-0.56 | $-0.54 | $-0.72 | $-0.56 | $-0.88 | $-0.79 | $-1.04 |
| Weighted Average Shares Outstanding | 96.17M | 96.17M | 97.50M | 96.08M | 96.08M | 94.32M | 93.97M | 93.91M | 93.91M | 66.05M | 54.93M | 54.94M | 54.62M | 54.90M | 54.88M | 54.81M | 54.84M | 54.88M | 51.80M | 54.88M |
| Weighted Average Shares Outstanding Diluted | 96.17M | 96.17M | 97.50M | 96.08M | 98.24M | 94.32M | 93.97M | 93.91M | 93.91M | 66.05M | 54.93M | 54.95M | 54.95M | 54.90M | 54.88M | 54.81M | 54.84M | 54.88M | 51.80M | 54.88M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $141.37M | $209.20M | $77.30M | $240.80M | $218.64M |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $141.37M | $209.20M | $77.30M | $240.80M | $218.64M |
| Net Receivables | $15.45M | $10.49M | $29.08M | $9.64M | $6.14M |
| Inventory | $- | $-11.20M | $-32.94M | $3.88M | $2.59M |
| Other Current Assets | $2.10M | $2.68M | $4.15M | $3.16M | $3.60M |
| Total Current Assets | $158.91M | $209.20M | $77.30M | $254.32M | $231.42M |
| Property Plant Equipment Net | $17.87M | $17.61M | $25.48M | $42.80M | $54.47M |
| Goodwill | $1 | $661 | $2.67K | $9.12K | $- |
| Intangible Assets | $58.00K | $9.34K | $19.33K | $41.16K | $53.38K |
| Goodwill and Intangible Assets | $58.00K | $10.00K | $22.00K | $50.28K | $53.38K |
| Long Term Investments | $3.68M | $3.80M | $3.49M | $4.59M | $1.34M |
| Tax Assets | $- | $-3.80M | $-3.49M | $-4.59M | $14.14M |
| Other Non-Current Assets | $2.46M | $19.68M | $43.92M | $36.71M | $5.48M |
| Total Non-Current Assets | $24.07M | $37.30M | $69.42M | $79.56M | $75.48M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $182.99M | $246.50M | $146.72M | $333.87M | $306.90M |
| Account Payables | $23.30M | $14.47M | $11.43M | $24.94M | $27.24M |
| Short Term Debt | $2.03M | $3.02M | $3.45M | $5.82M | $5.07M |
| Tax Payables | $201.87K | $69.00K | $182.00K | $711.29K | $488.05K |
| Deferred Revenue | $- | $2.14M | $4.15M | $5.75M | $4.07M |
| Other Current Liabilities | $11.81M | $9.82M | $12.19M | $21.85M | $20.60M |
| Total Current Liabilities | $37.34M | $29.52M | $31.40M | $64.65M | $61.09M |
| Long Term Debt | $4.53M | $1.13M | $6.28M | $9.24M | $20.51M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $934.00K | $21.42M | $9.77M | $6.03M | $4.69M |
| Total Non-Current Liabilities | $5.46M | $22.54M | $16.05M | $17.22M | $27.76M |
| Other Liabilities | $- | $-65.00K | $- | $- | $1 |
| Total Liabilities | $42.80M | $52.00M | $47.45M | $81.87M | $88.86M |
| Preferred Stock | $- | $- | $- | $- | $0 |
| Common Stock | $10.97M | $10.72M | $6.54M | $7.99M | $5.98M |
| Retained Earnings | $-238.86M | $-259.58M | $-258.53M | $-1.18B | $-195.20M |
| Accumulated Other Comprehensive Income Loss | $-8.13M | $-13.80M | $-5.62M | $8.15M | $-514.75M |
| Other Total Stockholders Equity | $376.20M | $457.16M | $325.50M | $1.15B | $-378.94M |
| Total Stockholders Equity | $140.19M | $194.50M | $99.27M | $252.01M | $218.05M |
| Total Equity | $140.19M | $194.50M | $99.27M | $252.01M | $218.05M |
| Total Liabilities and Stockholders Equity | $182.99M | $246.50M | $146.72M | $333.87M | $306.90M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $182.99M | $246.50M | $146.72M | $333.87M | $306.90M |
| Total Investments | $3.68M | $3.80M | $3.49M | $4.59M | $1.34M |
| Total Debt | $6.55M | $10.02M | $18.69M | $40.63M | $31.35M |
| Net Debt | $-134.81M | $-199.18M | $-58.61M | $-200.17M | $-187.28M |
Balance Sheet Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | June 30, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $46.44M | $71.19M | $101.53M | $141.37M | $149.10M | $173.96M | $192.29M | $209.19M | $212.67M | $247.97M | $74.11M | $77.30M | $98.19M | $125.48M | $152.46M | $240.80M | $285.82M | $218.64M | $87.57M | $138.48M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $46.44M | $71.19M | $101.53M | $141.37M | $149.10M | $173.96M | $192.29M | $209.19M | $212.67M | $247.97M | $74.11M | $77.30M | $98.19M | $125.48M | $152.46M | $240.80M | $285.82M | $218.64M | $87.57M | $138.48M |
| Net Receivables | $20.10M | $- | $15.10M | $13.98M | $- | $15.66M | $14.35M | $10.49M | $8.92M | $7.85M | $11.63M | $28.96M | $- | $- | $- | $9.64M | $1 | $6.14M | $3.27M | $29.32M |
| Inventory | $- | $- | $1.73M | $2.10M | $-16.94M | $-15.28M | $2.35M | $2.68M | $- | $3.77M | $3.39M | $-32.94M | $- | $- | $- | $3.88M | $4.22M | $2.59M | $2.70M | $2.69M |
| Other Current Assets | $2.21M | $26.72M | $1.73M | $17.80M | $22.06M | $4.49M | $2.35M | $2.68M | $4.11M | $3.77M | $3.39M | $4.15M | $11.94M | $13.11M | $7.35M | $3.16M | $11.07M | $3.60M | $29.37M | $13.29M |
| Total Current Assets | $68.76M | $96.73M | $119.56M | $158.91M | $149.10M | $195.54M | $210.24M | $223.07M | $225.69M | $259.95M | $90.44M | $77.30M | $110.14M | $138.59M | $159.81M | $254.32M | $301.12M | $231.42M | $115.72M | $177.56M |
| Property Plant Equipment Net | $18.97M | $20.25M | $19.46M | $17.87M | $14.48M | $15.97M | $16.91M | $17.61M | $17.04M | $18.82M | $20.55M | $25.48M | $27.15M | $29.21M | $30.69M | $42.80M | $51.34M | $54.47M | $51.89M | $55.47M |
| Goodwill | $- | $- | $3.81K | $5.46K | $3.30K | $5.68K | $781 | $661 | $-226 | $637 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $48.19K | $52.54K | $57.70K | $62.31K | $9.22K | $9.34K | $11.22K | $13.36K | $- | $- | $- | $- | $- | $- | $- | $53.38K | $- | $- |
| Goodwill and Intangible Assets | $43.00K | $49.46K | $52.00K | $58.00K | $61.00K | $68.00K | $10.00K | $10.00K | $11.00K | $14.00K | $18.00K | $22.00K | $26.00K | $25.00K | $32.00K | $50.28K | $53.15K | $53.38K | $57.57K | $29.69K |
| Long Term Investments | $- | $- | $- | $3.68M | $- | $- | $- | $1.66M | $- | $- | $- | $3.67M | $- | $- | $- | $3.32M | $- | $1.34M | $692.09K | $716.53K |
| Tax Assets | $- | $- | $- | $-3.68M | $- | $- | $- | $-1.66M | $- | $- | $- | $-3.67M | $- | $- | $- | $-3.32M | $- | $14.14M | $11.63M | $1.76M |
| Other Non-Current Assets | $5.28M | $5.76M | $6.82M | $6.14M | $5.97M | $5.94M | $5.77M | $5.83M | $5.37M | $6.19M | $6.57M | $43.92M | $33.61M | $32.76M | $30.87M | $36.71M | $26.70M | $5.48M | $5.07M | $5.45M |
| Total Non-Current Assets | $24.30M | $26.06M | $26.33M | $24.07M | $20.51M | $21.98M | $22.69M | $23.44M | $22.42M | $25.02M | $27.14M | $69.42M | $60.79M | $61.99M | $61.60M | $79.56M | $78.10M | $75.48M | $69.34M | $63.43M |
| Other Assets | $- | $- | $-1.00K | $- | $-185.31M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1 | $- |
| Total Assets | $93.06M | $122.78M | $145.90M | $182.99M | $-15.70M | $217.52M | $232.93M | $246.52M | $248.12M | $284.98M | $117.58M | $146.72M | $170.92M | $200.58M | $221.41M | $333.87M | $379.21M | $306.90M | $185.06M | $240.99M |
| Account Payables | $22.50M | $21.31M | $18.08M | $23.30M | $16.65M | $19.09M | $19.94M | $14.47M | $15.37M | $16.34M | $11.42M | $11.43M | $12.17M | $16.34M | $17.18M | $24.94M | $27.73M | $27.24M | $21.83M | $28.80M |
| Short Term Debt | $1.08M | $839.13K | $446.00K | $2.03M | $2.16M | $2.38M | $2.22M | $3.02M | $3.40M | $2.12M | $2.33M | $3.45M | $3.26M | $4.35M | $4.47M | $5.82M | $4.51M | $5.07M | $4.74M | $4.66M |
| Tax Payables | $211.00K | $218.27K | $180.00K | $223.00K | $193.00K | $187.00K | $97.00K | $69.00K | $405.00K | $400.00K | $137.00K | $182.00K | $149.00K | $85.00K | $312.00K | $711.29K | $- | $488.05K | $181.12K | $262.08K |
| Deferred Revenue | $- | $- | $4.81M | $223.00K | $2.29M | $2.26M | $2.19M | $2.14M | $2.91M | $3.01M | $3.79M | $4.15M | $4.29M | $4.88M | $3.38M | $5.75M | $15.97M | $4.07M | $5.92M | $7.06M |
| Other Current Liabilities | $7.12M | $5.54M | $7.78M | $11.79M | $10.15M | $9.45M | $8.33M | $9.82M | $6.31M | $8.56M | $8.35M | $12.19M | $13.95M | $13.04M | $13.49M | $21.85M | $34.55M | $20.60M | $18.27M | $14.39M |
| Total Current Liabilities | $30.91M | $29.44M | $26.48M | $37.34M | $31.44M | $33.37M | $32.78M | $29.52M | $28.39M | $30.43M | $26.03M | $31.40M | $33.81M | $38.70M | $38.83M | $64.65M | $70.34M | $61.09M | $53.22M | $59.13M |
| Long Term Debt | $7.04M | $6.78M | $6.79M | $4.53M | $94.00K | $187.00K | $680.00K | $1.13M | $1.42M | $1.95M | $2.27M | $7.15M | $8.30M | $9.33M | $8.46M | $11.16M | $21.04M | $22.91M | $23.48M | $25.22M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $2.70M | $3.99M | $4.38M | $- | $926.00K | $1.69M | $- | $- | $2.62M | $1.85M | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.67M | $1.62M | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $1.07M | $1.00M | $965.00K | $934.00K | $11.55M | $15.73M | $16.00M | $21.42M | $5.33M | $6.50M | $7.22M | $8.90M | $7.63M | $6.06M | $4.94M | $3.68M | $1.52M | $1.89M | $3.25M | $3.22M |
| Total Non-Current Liabilities | $8.11M | $8.29M | $7.76M | $5.46M | $14.35M | $19.91M | $21.06M | $22.54M | $7.67M | $10.13M | $9.49M | $16.05M | $20.22M | $18.87M | $13.40M | $17.22M | $25.08M | $27.76M | $28.88M | $31.67M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1 | $- | $1 |
| Total Liabilities | $39.02M | $37.74M | $34.24M | $42.80M | $45.79M | $53.28M | $53.84M | $52.06M | $36.06M | $40.56M | $35.52M | $47.45M | $54.03M | $57.56M | $52.23M | $81.87M | $95.43M | $88.86M | $82.10M | $90.81M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $0 | $0 | $0 | $0 |
| Common Stock | $10.98M | $11.80M | $10.97M | $10.97M | $10.95M | $10.95M | $10.72M | $10.72M | $10.71M | $10.71M | $6.54M | $6.54M | $6.53M | $6.53M | $6.52M | $7.99M | $6.95M | $5.98M | $4.34M | $4.67M |
| Retained Earnings | $-263.33M | $-250.41M | $-266.21M | $-238.86M | $-61.50M | $-210.94M | $-280.14M | $-259.58M | $-220.34M | $-203.05M | $-275.22M | $-258.53M | $-244.86M | $-220.82M | $-987.99M | $-1.18B | $-109.52M | $-195.20M | $-133.46M | $-103.04M |
| Accumulated Other Comprehensive Income Loss | $-8.36M | $-13.06M | $-11.21M | $-8.13M | $-14.37M | $-10.45M | $-10.22M | $-13.80M | $-34.12M | $-18.74M | $-7.54M | $-5.62M | $-3.05M | $649.00K | $-2.19M | $8.15M | $-703.64M | $-514.75M | $-493.68M | $-532.81M |
| Other Total Stockholders Equity | $314.75M | $313.15M | $378.10M | $376.20M | $3.42M | $374.68M | $458.73M | $457.11M | $455.80M | $455.49M | $358.29M | $356.88M | $358.27M | $356.66M | $1.15B | $1.15B | $968.70M | $1.94B | $662.39M | $688.70M |
| Total Stockholders Equity | $54.03M | $85.05M | $111.65M | $140.19M | $-61.50M | $164.24M | $179.09M | $194.45M | $212.05M | $244.41M | $82.06M | $99.27M | $116.89M | $143.02M | $169.18M | $252.01M | $283.79M | $218.05M | $102.96M | $150.18M |
| Total Equity | $54.03M | $85.05M | $111.65M | $140.19M | $-61.50M | $164.24M | $179.09M | $194.45M | $212.05M | $244.41M | $82.06M | $99.27M | $116.89M | $143.02M | $169.18M | $252.01M | $283.79M | $218.05M | $102.96M | $150.18M |
| Total Liabilities and Stockholders Equity | $93.06M | $122.78M | $145.89M | $182.99M | $-15.70M | $217.52M | $232.93M | $246.52M | $248.12M | $284.98M | $117.58M | $146.72M | $170.92M | $200.58M | $221.40M | $333.87M | $379.21M | $306.90M | $185.06M | $240.99M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $93.06M | $122.78M | $145.89M | $182.99M | $-15.70M | $217.52M | $232.93M | $246.52M | $248.12M | $284.98M | $117.58M | $146.72M | $170.92M | $200.58M | $221.40M | $333.87M | $379.21M | $306.90M | $185.06M | $240.99M |
| Total Investments | $- | $- | $- | $3.68M | $- | $- | $- | $1.66M | $- | $- | $- | $3.67M | $- | $- | $- | $3.32M | $- | $1.34M | $692.09K | $716.53K |
| Total Debt | $8.12M | $8.16M | $7.24M | $6.55M | $2.25M | $2.56M | $2.90M | $10.02M | $3.44M | $5.30M | $5.43M | $18.69M | $13.12M | $13.68M | $23.60M | $40.63M | $28.54M | $31.35M | $30.72M | $33.60M |
| Net Debt | $-38.32M | $-63.03M | $-94.29M | $-134.81M | $-146.85M | $-171.40M | $-189.39M | $-199.17M | $-209.23M | $-242.67M | $-68.68M | $-58.61M | $-85.07M | $-111.80M | $-128.86M | $-200.17M | $-257.29M | $-187.28M | $-56.85M | $-104.88M |
Annual Cash Flow
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Net Income | $-72.73M | $-96.27M | $-97.81M | $-195.67M | $-195.20M |
| Depreciation and Amortization | $-14.00M | $13.16M | $8.38M | $12.83M | $7.24M |
| Deferred Income Tax | $- | $- | $184.00K | $-534.70K | $593.53K |
| Stock Based Compensation | $6.02M | $5.03M | $3.12M | $-1.39M | $19.56M |
| Change in Working Capital | $953.00K | $22.32M | $-22.77M | $-19.14M | $3.90M |
| Accounts Receivables | $- | $- | $2.15M | $-2.54M | $38.13K |
| Inventory | $- | $- | $-16.18M | $2.85M | $-598.62K |
| Accounts Payables | $8.42M | $3.46M | $-7.56M | $-6.23M | $-8.69M |
| Other Working Capital | $-7.47M | $18.86M | $-1.19M | $-13.22M | $13.15M |
| Other Non Cash Items | $99.00K | $66.00K | $656.00K | $804.50K | $1.16M |
| Net Cash Provided by Operating Activities | $-79.65M | $-55.70M | $-108.24M | $-203.10M | $-163.34M |
| Investments in Property Plant and Equipment | $-677.00K | $-754.00K | $-918.00K | $-3.39M | $-6.35M |
| Acquisitions Net | $- | $7.61K | $511.01K | $- | $- |
| Purchases of Investments | $-285.00K | $-123.00K | $-119.00K | $-126.32K | $-73.72K |
| Sales Maturities of Investments | $154.00K | $770.00K | $-511.01K | $- | $- |
| Other Investing Activities | $- | $-612 | $604.00K | $-1.23K | $-107.79K |
| Net Cash Used for Investing Activities | $-808.00K | $-100.00K | $-433.00K | $-3.51M | $-6.43M |
| Debt Repayment | $- | $- | $-582.92K | $-303.00K | $-1.18M |
| Common Stock Issued | $6.92M | $194.59M | $978.00K | $184.51M | $237.06M |
| Common Stock Repurchased | $-154.00K | $- | $- | $-690.44K | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $- | $-474.00K | $-121.08K | $-42.92K | $-25.30M |
| Net Cash Used Provided by Financing Activities | $6.77M | $194.10M | $274.00K | $183.40M | $232.32M |
| Effect of Forex Changes on Cash | $5.87M | $-6.50M | $-10.65M | $27.01M | $54.65K |
| Net Change in Cash | $-67.83M | $131.90M | $-119.05M | $3.80M | $62.60M |
| Cash at End of Period | $141.37M | $209.20M | $77.30M | $240.80M | $218.64M |
| Cash at Beginning of Period | $209.19M | $77.30M | $196.35M | $237.00M | $156.03M |
| Operating Cash Flow | $-79.65M | $-55.70M | $-108.24M | $-203.10M | $-163.34M |
| Capital Expenditure | $-677.00K | $-754.00K | $-918.00K | $-3.39M | $-6.35M |
| Free Cash Flow | $-80.33M | $-56.45M | $-109.16M | $-206.48M | $-169.70M |
Cash Flow Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-30.44M | $-33.12M | $-27.34M | $-11.19M | $-16.74M | $-24.24M | $-20.56M | $-39.24M | $-17.29M | $-23.04M | $-16.71M | $-13.67M | $-24.03M | $-30.65M | $-29.45M | $-39.48M | $-30.96M | $-48.20M | $-40.91M | $-57.08M |
| Depreciation and Amortization | $-152.00K | $-1.46M | $53.00K | $-10.93M | $-3.44M | $597.00K | $-228.00K | $12.02M | $-109.00K | $1.85M | $-599.00K | $-1.33M | $1.09M | $7.14M | $1.48M | $-7.90M | $3.77M | $13.05M | $1.55M | $2.24M |
| Deferred Income Tax | $- | $- | $- | $18.00K | $47.00K | $46.00K | $- | $- | $- | $- | $-9.00K | $57.00K | $70.00K | $57.00K | $- | $214.00K | $148.00K | $-907.00K | $109.00K | $159.05K |
| Stock Based Compensation | $1.59M | $1.52M | $1.96M | $1.22M | $1.35M | $1.81M | $1.63M | $1.61M | $975.00K | $1.08M | $1.36M | $-956.00K | $1.55M | $1.09M | $1.43M | $1.83M | $-74.00K | $-5.96M | $3.07M | $6.99M |
| Change in Working Capital | $5.91M | $-3.82M | $-9.35M | $7.19M | $-795.00K | $-3.79M | $-1.65M | $1.68M | $-3.67M | $9.84M | $14.47M | $-2.33M | $-3.68M | $-7.54M | $-9.22M | $11.94M | $-15.53M | $1.91M | $-13.92M | $18.49M |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-24.00K | $-1.00K | $74.00K | $2.10M | $-96.00K | $-1.98M | $6.00K | $-8.26M | $38.13K |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-1.64M | $468.00K | $-6.60M | $-8.40M | $35.00K | $3.73M | $969.00K | $-2.40M | $246.76K |
| Accounts Payables | $1.96M | $1.76M | $-4.80M | $6.73M | $-1.73M | $-1.06M | $4.48M | $-2.24M | $-195.00K | $5.91M | $-19.00K | $-424.00K | $-3.97M | $-598.00K | $-2.57M | $1.68M | $-8.45M | $4.90M | $-3.21M | $4.80M |
| Other Working Capital | $3.96M | $-5.58M | $56.00K | $459.00K | $933.00K | $-2.73M | $-6.13M | $3.92M | $-3.48M | $3.93M | $14.49M | $-1.88M | $291.00K | $-7.02M | $-8.75M | $10.32M | $-8.82M | $-3.97M | $-8.30M | $26.81M |
| Other Non Cash Items | $637.00K | $1.80M | $-1.00K | $1.00K | $-2.00K | $22.00K | $-33.00K | $44.00K | $44.00K | $25.00K | $-4.00K | $-501.00K | $2.13M | $-331.00K | $-455.00K | $79.00K | $564.00K | $-951.00K | $528.00K | $415.68K |
| Net Cash Provided by Operating Activities | $-22.46M | $-35.07M | $-34.69M | $-13.69M | $-19.57M | $-25.55M | $-20.84M | $-23.89M | $-20.05M | $-10.25M | $-1.48M | $-18.79M | $-22.95M | $-30.30M | $-36.20M | $-33.53M | $-42.23M | $-40.16M | $-49.68M | $-28.95M |
| Investments in Property Plant and Equipment | $-396.00K | $-732.00K | $-1.33M | $-352.00K | $-50.00K | $-164.00K | $-111.00K | $-12.00K | $-373.00K | $-238.00K | $-131.00K | $-910.00K | $13.00K | $171.00K | $-184.00K | $-541.00K | $-777.00K | $-513.00K | $-930.00K | $-1.85M |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-171.00K | $858.00K | $-858.00K | $11.00K | $-269.00K | $-27.00K | $- | $26.00K | $130.00K | $-239.00K | $-40.00K | $- | $- | $1.00K | $-1.00K | $-91.00K | $-5.00K | $-7.00K | $- | $-56.34K |
| Sales Maturities of Investments | $458.00K | $564.00K | $62.00K | $- | $- | $-149.00K | $153.00K | $-52.00K | $396.00K | $247.00K | $179.00K | $- | $3.00K | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $1.00K | $-1.00K | $154.00K | $-3.00K | $-1.00K | $153.00K | $4.00K | $-1.00K | $1.00K | $3.00K | $436.00K | $41.00K | $1.00K | $-1.00K | $-10.00K | $-9.00K | $103.00K | $-114.00K | $-799 |
| Net Cash Used for Investing Activities | $-109.00K | $691.00K | $-2.13M | $-187.00K | $-322.00K | $-341.00K | $42.00K | $-34.00K | $152.00K | $-229.00K | $11.00K | $-474.00K | $54.00K | $172.00K | $-185.00K | $-633.00K | $-782.00K | $-520.00K | $-930.00K | $-1.91M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-1.11M |
| Common Stock Issued | $- | $- | $- | $-35.00K | $-837.00K | $- | $- | $- | $-668.00K | $195.51M | $40.00K | $184.00K | $-638.00K | $812.00K | $620.00K | $-102.00K | $-478.00K | $6.00K | $151.02M | $156.35M |
| Common Stock Repurchased | $7.00K | $-33.00K | $-62.00K | $-189.00K | $-837.00K | $- | $-14.00K | $- | $-668.00K | $- | $- | $- | $-997.00K | $- | $- | $203.00K | $-410.00K | $56.00K | $-412.00K | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $- | $- | $- | $- | $- | $- | $- | $4.00K | $-150.00K | $-159.00K | $-169.00K | $-166.00K | $-177.00K | $-181.00K | $-180.00K | $-177.00K | $-160.00K | $-1.00K | $- | $-266.15K |
| Net Cash Used Provided by Financing Activities | $7.00K | $-33.00K | $-62.00K | $-189.00K | $-837.00K | $7.81M | $-14.00K | $-283.00K | $-818.00K | $195.35M | $-129.00K | $377.00K | $-1.17M | $631.00K | $440.00K | $-76.00K | $-1.05M | $61.00K | $150.61M | $154.82M |
| Effect of Forex Changes on Cash | $2.79M | $-896.00K | $-2.96M | $6.29M | $-4.09M | $-241.00K | $3.91M | $20.73M | $-14.59M | $-11.01M | $-1.59M | $-2.01M | $-3.22M | $2.52M | $-7.94M | $9.19M | $12.54M | $6.10M | $-5.81M | $407.20K |
| Net Change in Cash | $-19.77M | $-35.31M | $-39.84M | $-7.77M | $-24.83M | $-18.33M | $-16.91M | $-3.48M | $-35.30M | $173.86M | $-3.19M | $-20.89M | $-27.29M | $-26.98M | $-43.89M | $-25.05M | $-31.51M | $-34.52M | $94.19M | $128.01M |
| Cash at End of Period | $46.44M | $66.21M | $101.53M | $141.37M | $149.13M | $173.96M | $192.29M | $209.19M | $212.67M | $247.97M | $74.11M | $77.30M | $98.19M | $125.48M | $152.46M | $196.35M | $221.40M | $252.92M | $287.44M | $218.64M |
| Cash at Beginning of Period | $66.21M | $101.53M | $141.37M | $149.13M | $173.96M | $192.29M | $209.19M | $212.67M | $247.97M | $74.11M | $77.30M | $98.19M | $125.48M | $152.46M | $196.35M | $221.40M | $252.92M | $287.44M | $193.25M | $90.63M |
| Operating Cash Flow | $-22.46M | $-35.07M | $-34.69M | $-13.69M | $-19.57M | $-25.55M | $-20.84M | $-23.89M | $-20.05M | $-10.25M | $-1.48M | $-18.79M | $-22.95M | $-30.30M | $-36.20M | $-33.53M | $-42.23M | $-40.16M | $-49.68M | $-28.95M |
| Capital Expenditure | $-396.00K | $-732.00K | $-1.33M | $-352.00K | $-50.00K | $-164.00K | $-111.00K | $-12.00K | $-373.00K | $-238.00K | $-131.00K | $-910.00K | $13.00K | $171.00K | $-184.00K | $-541.00K | $-777.00K | $-513.00K | $-930.00K | $-1.85M |
| Free Cash Flow | $-22.85M | $-35.80M | $-36.03M | $-14.04M | $-19.62M | $-25.72M | $-20.95M | $-23.90M | $-20.42M | $-10.49M | $-1.61M | $-19.70M | $-22.94M | $-30.13M | $-36.39M | $-34.07M | $-43.01M | $-40.68M | $-50.61M | $-30.80M |
DBV Technologies S.A Stock Forecast
Analyst ratings, price targets, and earnings estimates for DBVT.
DBVT Analyst Ratings
Strong Buy
Based on 4 analysts in the past 3 months
Recent Price Targets
Recommendation Trends
Analyst Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Latest Price Target Updates
| Date | Analyst | Firm | Price Target | Price When Posted | Upside |
|---|
DBV Technologies S.A Dividends
Explore DBV Technologies S.A's dividend history, including dividend yield, payout ratio, and historical payments.
Peers: Biotechnology
This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.
| Company | Market Cap | Price | EPS | P/E Ratio | P/B Ratio |
|---|---|---|---|---|---|
POINT Biopharma Global Inc.
PNT
|
$1.33B | $12.50 | $1.04 | $7.02 | $1.42 |
ORIC Pharmaceuticals, Inc.
ORIC
|
$546.91M | $7.70 | $-1.83 | $-4.40 | $2.31 |
Lyra Therapeutics, Inc.
LYRA
|
$11.46M | $0.18 | $-1.43 | $-0.14 | $1.16 |
Inhibrx Biosciences, Inc.
INBX
|
$204.83M | $14.15 | $-5.12 | $-7.42 | $41.17 |
ESSA Pharma Inc.
EPIX
|
$72.35M | $1.63 | $0.00 | $0.00 | $2.09 |
Eliem Therapeutics, Inc.
ELYM
|
$342.68M | $5.11 | $ | $ | $ |
Opthea Limited
OPT
|
$59.06M | $3.07 | $-0.35 | $-0.67 | $-1.94 |
Molecular Partners AG
MOLN
|
$161.88M | $4.39 | $-1.59 | $-2.56 | $0.98 |
Edgewise Therapeutics, Inc.
EWTX
|
$2.41B | $25.28 | $-1.45 | $-18.44 | $5.37 |
iTeos Therapeutics, Inc.
ITOS
|
$274.62M | $7.19 | $-3.32 | $-2.31 | $0.53 |
Centessa Pharmaceuticals plc
CNTA
|
$2.22B | $16.87 | $-1.57 | $-5.07 | $3.24 |
Nuvalent, Inc.
NUVL
|
$5.33B | $74.48 | $-3.93 | $-19.94 | $4.86 |
Tarsus Pharmaceuticals, Inc.
TARS
|
$1.78B | $46.47 | $-3.07 | $-18.02 | $9.27 |
Genfit S.A.
GNFT
|
$174.53M | $3.50 | $-0.58 | $-6.10 | $2.60 |
Ikena Oncology, Inc.
IKNA
|
$54.75M | $1.36 | $-1.02 | $-1.61 | $0.63 |
Anebulo Pharmaceuticals, Inc.
ANEB
|
$58.75M | $1.43 | $-0.32 | $-8.44 | $18.15 |
Celcuity Inc.
CELC
|
$372.41M | $10.03 | $-2.69 | $-5.41 | $2.47 |
MediciNova, Inc.
MNOV
|
$72.10M | $1.47 | $-0.17 | $-8.58 | $1.18 |
Rezolute, Inc.
RZLT
|
$226.40M | $3.74 | $-1.33 | $-3.24 | $1.83 |
Innate Pharma S.A.
IPHA
|
$167.20M | $2.00 | $-0.09 | $-27.85 | $4.06 |
HCW Biologics Inc.
HCWB
|
$14.90M | $0.33 | $-0.70 | $-1.77 | $3.28 |
Related Metrics
Explore detailed financial metrics and analysis for DBVT.